HMGB1 and neoplasm: On the other hand, these therapies can also induce immunological cell death (ICD) and convert tumor into an in situ vaccine, leading to the release of damage-associated molecular pattern molecules (DAMPs), such as calreticulin, high mobility group box 1 (HMGB1) or adenosine triphosphate (ATP), which activate apoptotic or necroptotic pathways and reactive immune responses (76).